Diagnosis and management of common dermatoses in children: Atopic, seborrheic, and contact dermatitis

Clinical Pediatrics

Volumn 47, Issue 4, 2008, Pages 332-346

  Fleischer Jr , Alan B ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Calcineurin inhibitor; Eczema; Inflammation; Skin disease

Indexed keywords

AMCINONIDE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CALCINEURIN INHIBITOR; CLOBETASOL PROPIONATE; CORTICOSTEROID; CYCLOSPORIN; DESOXIMETASONE; DIFLORASONE DIACETATE; EMOLLIENT AGENT; FLUOCINONIDE; FLUTICASONE PROPIONATE; GAMMA INTERFERON; HALCINONIDE; HYDROCORTISONE; HYDROCORTISONE ACETATE; HYDROCORTISONE BUTYRATE; KETOCONAZOLE; MICONAZOLE NITRATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIMECROLIMUS; STEROID; TACROLIMUS; ULOBETASOL PROPIONATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XOLEGEL;

ACNE; ADJUVANT THERAPY; ALGORITHM; ANTIINFLAMMATORY ACTIVITY; ATOPY; BONE DENSITY; CATARACTOGENESIS; CHILD CARE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTACT DERMATITIS; CUSHING SYNDROME; DANDRUFF; DIAPER DERMATITIS; DIFFERENTIAL DIAGNOSIS; DRUG MECHANISM; DRUG METABOLISM; GLAUCOMA; GROWTH RETARDATION; HEADACHE; HEALTH CARE COST; HERPES SIMPLEX; HUMAN; HYDROGEL; HYPERSALIVATION; HYPOPIGMENTATION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MONOTHERAPY; PAIN; PATHOGENESIS; PATIENT EDUCATION; PERIORAL DERMATITIS; PHOTOTHERAPY; PREVALENCE; PRURITUS; QUALITY OF LIFE; REVIEW; ROSACEA; SEBORRHEA; SIDE EFFECT; SKIN ATROPHY; SKIN BURNING SENSATION; SKIN CARE; SKIN IRRITATION; STRIA; TELANGIECTASIA; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; DERMATITIS, CONTACT; DERMATITIS, SEBORRHEIC; HISTAMINE H1 ANTAGONISTS; HUMANS; SKIN; SKIN DISEASES; TREATMENT OUTCOME;

EID: 42049099269     PISSN: 00099228     EISSN: None     Source Type: Journal    
DOI: 10.1177/0009922807309421     Document Type: Review

References (112)

1. Lee DJ, Eichenfield LF Atopic, contact, and seborrheic dermatitis in adolescents. Adolesc Med. 2001 ; 12: 269-283.
2. Shin HT Diaper dermatitis that does not quit. Dermatol Ther. 2005 ; 18: 124-135.
3. Singleton JK Pediatric dermatoses: three common skin disruptions in infancy. Nurse Pract. 1997 ; 22: 32-33, 37, 43-44, 49-50.
4. Lapidus CS, Kerr PE Social impact of atopic dermatitis. Med Health R I. 2001 ; 84: 294-295.
5. Carroll CL, Balkrishnan R., Feldman SR, Fleischer AB Jr, Manuel JC The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol. 2005 ; 22: 192-199.
6. Fivenson D., Arnold RJG, Kaniecki DJ, Cohen JL, Frech F., Finlay AY The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organization. J Manag Care Pharm. 2002 ; 8: 333-342.
7. Zuberbier T., Orlow SJ, Paller AS, et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol. 2006 ; 118: 226-232.
8. Rudikoff D., Lebwohl M. Atopic dermatitis. Lancet. 1998 ; 351: 1715-1721.
9. Dahl RE, Bernhisel-Broadbent J., Scanlon-Holdford S., Sampson HA, Lupo M. Sleep disturbances in children with atopic dermatitis. Arch Pediatr Adolesc Med. 1995 ; 149: 856-860.
10. Paller AS, McAlister RO, Doyle JJ, Jackson A. Perceptions of physicians and pediatric patients about atopic dermatitis, its impact, and its treatment. Clin Pediatr (Phila). 2002 ; 41: 323-332.
11. Su JC, Kemp AS, Varigos GA, Nolan TM Atopic eczema: its impact on the family and financial cost. Arch Dis Child. 1997 ; 76: 159-162.
12. Ellis CN, Drake LA, Prendergast MM, et al. Cost of atopic dermatitis and eczema in the United States. J Am Acad Dermatol. 2002 ; 46: 361-370.
13. Larsen FS, Hanifin JM Epidemiology of atopic dermatitis. Immunol Allergy Clin North Am. 2002 ; 22: 1-24.
14. Laughter D., Istvan JA, Tofte SJ, Hanifin JM The prevalence of atopic dermatitis in Oregon schoolchildren. J Am Acad Dermatol. 2000 ; 43: 649-655.
15. Wuthrich B. Epidemiology and natural history of atopic dermatitis. Allergy Clin Immunol Int. 1996 ; 8: 77-82.
16. Rajka G, ed. Essential Aspects of Atopic Dermatitis. Berlin, Germany: Springer-Verlag; 1989: 4-55.
17. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet. 1998 ; 351: 1225-1232.
18. Bergmann RL, Edenharter G., Bergmann KE, et al. Atopic dermatitis in early infancy predicts allergic airway disease at 5 years. Clin Exp Allergy. 1998 ; 28: 965-970.
19. Eichenfield LF, Hanifin JM, Beck LA, et al. Atopic dermatitis and asthma: parallels in the evolution of treatment. Pediatrics. 2003 ; 111: 608-616.
20. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1980 ; 92: 44-47.
21. Eichenfield LF, Hanifin JM, Luger TA, Stevens SR, Pride HB Consensus conference on pediatric atopic dermatitis. J Am Acad Dermatol. 2003 ; 49: 1088-1095.
22. Sidbury R., Poorsattar S. Pediatric atopic dermatitis: should we treat it differently ? Dermatol Ther. 2006 ; 19: 83-90.
23. Correale CE, Walker C., Murphy L., Craig TJ Atopic dermatitis: a review of diagnosis and treatment. Am Fam Physician. 1999 ; 60: 1191-1198.
24. Sanfilippo AM, Barrio V., Kulp-Shorten C., Callen JP Common pediatric and adolescent skin conditions. J Pediatr Adolesc Gynecol. 2003 ; 16: 269-283.
25. Clarke P. Why am I so itchy? Aust Fam Physician. 2004 ; 33: 489-494.
26. Sweeney SM, Wiss K., Mallory SB Inflammatory tinea pedis/manuum masquerading as bacterial cellulitis. Arch Pediatr Adolesc Med. 2002 ; 156: 1149-1152.
27. Leung DYM, Boguniewicz M., Howell MD, Nomura I., Hamid QA New insights into atopic dermatitis. J Clin Invest. 2004 ; 113: 651-657.
28. Ring J. Diseases due to environmental factors. Available from www.science.ngfn.de/dateien/NUWS31T05_Ring.pdf#search= %22EDC%20atopic%20dermatitis%22. Accessed September 28, 2006.
29. Weidinger S., Illig T., Baurecht H., et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol. 2006 ; 118: 214-219.
30. Coderch L., Lopez O., de la Maza A., Parra JL Ceramides and skin function. Am J Clin Dermatol. 2003 ; 4: 107-129.
31. Imokawa G., Abe A., Jin K., Higaki Y., Kawashima M., Hidano A. Decreased level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in atopic dry skin ? J Invest Dermatol. 1991 ; 96: 523-526.
32. Ellis C., Luger T., Abeck D., et al. International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies. Br J Dermatol. 2003 ; 148 (suppl 63). 3-10.
33. Lever R., MacDonald C., Waugh P., Aitchison T. Randomised controlled trial of advice on an egg exclusion diet in young children with atopic eczema and sensitivity to eggs. Pediatr Allergy Immunol. 1998 ; 9: 13-19.
34. Leung DYM, Bieber T. Atopic dermatitis. Lancet. 2003 ; 361: 151-160.
35. Dohil MA, Eichenfield LF A treatment approach for atopic dermatitis. Pediatr Ann. 2005 ; 34: 201-210.
36. Darsow U., Lübbe J., Taïeb A., et al. Position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol. 2005 ; 19: 286-295.
37. Simpson EL, Hanifin JM Atopic dermatitis. Med Clin North Am. 2006 ; 90: 149-167.
38. Hughes J., Rustin M. Corticosteroids. Clin Dermatol. 1997 ; 15: 715-721.
39. Sulzberger MB, Witten VH, Smith CC Hydrocortisone (compound F) acetate ointment in dermatological therapy. JAMA. 1953 ; 151: 468-472.
40. Hoare C., Li Wan Po AL, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess. 2000 ; 4: 1-191.
41. Del Rosso J., Friedlander SF Corticosteroids: options in the era of steroid-sparing therapy. J Am Acad Dermatol. 2005 ; 53: S50 - S58.
42. Thomas KS, Armstrong S., Avery A., et al. Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema. BMJ. 2002 ; 324: 1-7.
43. Nuutinen P., Riekki R., Parikka M., et al. Modulation of collagen synthesis and mRNA by continuous and intermittent use of topical hydrocortisone in human skin. Br J Dermatol. 2003 ; 148: 39-45.
44. Hanifin JM, Cooper KD, Ho VC, et al. Guidelines of care for atopic dermatitis. J Am Acad Dermatol. 2004 ; 50: 391-404.
45. National Prescribing Centre. Atopic eczema in primary care. MeReC Bull. 2003 ; 14: 1-4.
46. Turpeinen M., Salo OP, Leisti S. Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease. Br J Dermatol. 1986 ; 115: 475-484.
47. Aalto-Korte K., Turpeinen M. Pharmacokinetics of topical hydrocortisone at plasma level after applications once or twice daily in patients with widespread dermatitis. Br J Dermatol. 1995 ; 133: 259-263.
48. Charman CR, Morris AD, Williams HC Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000 ; 142: 931-936.
49. Grassberger M., Baumruker T., Enz A., et al. A novel antiinflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol. 1999 ; 141: 264-273.
50. Bornhövd EC, Burgdorf WHC, Wollenberg A. Immunomodulatory macrolactams for topical treatment of inflammatory skin diseases. Curr Opin Investig Drugs. 2002 ; 3: 708-712.
51. Ruzicka T., Bieber T., Schöpf E., et al. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med. 1997 ; 337: 816-821.
52. Reitamo S., Rustin M., Ruzicka T., et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol. 2002 ; 109: 547-555.
53. Boguniewicz M., Fiedler VC, Raimer S., Lawrence ID, Leung DYM, Hanifin JM A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. J Allergy Clin Immunol. 1998 ; 102: 637-644.
54. Housman TS, Norton AB, Feldman SR, et al. Tacrolimus ointment: utilization patterns in children under age 2 years. Dermatol Online J. 2004 ; 10: 2.
55. Meurer M., Fartasch M., Albrecht G., et al. Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology. 2004 ; 208: 365-372.
56. Eichenfield LF, Lucky AW, Boguniewicz M., et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 2002 ; 46: 495-504.
57. Wahn U., Bos JD, Goodfield M., et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002 ; 110: e2.
58. Meurer M., Fölster-Holst R., Wozel G., Weidinger G., Jünger M., Bräutigam M. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology. 2002 ; 205: 271-277.
59. McKenna SP, Whalley D., de Prost Y., et al. Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel®, SDZ ASM 981): impact on quality of life and health-related quality of life. J Eur Acad Dermatol Venereol. 2006 ; 20: 248-254.
60. Papp KA, Werfel T., Fölster-Holst R., et al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. J Am Acad Dermatol. 2005 ; 52: 240-246.
61. Lübbe J., Friedlander SF, Cribier B., et al. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice. Am J Clin Dermatol. 2006 ; 7: 121-131.
62. Ho VC, Gupta A., Kaufmann R., et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr. 2003 ; 142: 155-162.
63. Staab D., Pariser D., Gottlieb AB, et al. Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel®) in infants with atopic dermatitis-a multicenter, 3-week, open-label study. Pediatr Dermatol. 2005 ; 22: 465-471.
64. Hultsch T. Elidel (Pimecrolimus) cream 1% safety. Available from http://www.fda.gov/ohrms/dockets/ac/05/slides/2005- 4089s2_02_02_Novartis%20Core%20Safety%20(CS).pdf. Accessed July 31, 2007.
65. Harper J., Smith C., Rubins A., et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. J Invest Dermatol. 2005 ; 124: 695-699.
66. Allen BR, Lakhanpaul M., Morris A., et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child. 2003 ; 88: 969-973.
67. Thaçi D., Steinmeyer K., Ebelin M. -E, Scott G., Kaufmann R. Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective: an open study. Dermatology. 2003 ; 207: 37-42.
68. Van Leent EJM, Ebelin M. -E, Burtin P., Dorobek B., Spuls PI, Bos JD Low systemic exposure after repeated topical application of pimecrolimus (Elidel®, SDZ ASM 981) in patients with atopic dermatitis. Dermatology. 2002 ; 204: 63-68.
69. Billich A., Aschauer H., Aszódi A., Stuetz A. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm. 2004 ; 269: 29-35.
70. Protopic [prescribing information]. Deerfield, IL: Astellas Pharma Inc ; 2006.
71. Reitamo S., Wollenberg A., Schöpf E., et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol. 2000 ; 136: 999-1006.
72. Fonacier L., Spergel J., Charlesworth EN, et al. Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2005 ; 115: 1249-1253.
73. Hultsch T., Kapp A., Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology. 2005 ; 211: 174-187.
74. Lebwohl M., Gower T. A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis. Medscape Gen Med. 2006 ; 8: 8.
75. Ring J., Barker J., Behrendt H., et al. Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum. J Eur Acad Dermatol Venereol. 2005 ; 19: 663-671.
76. Bieber T., Cork M., Ellis C., et al. Consensus statement on the safety profile of topical calcineurin inhibitors. Dermatology. 2005 ; 211: 77-78.
77. Berger TG, Duvic M., Van Voorhees AS, Frieden IJ The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol. 2006 ; 54: 818-823.
78. Klein PA, Clark RAF. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol. 1999 ; 135: 1522-1525.
79. Abramovits W. A clinician's paradigm in the treatment of atopic dermatitis. J Am Acad Dermatol. 2005 ; 53: S70 - S77.
80. Sidbury R., Hanifin JM Systemic therapy of atopic dermatitis. Clin Exp Dermatol. 2000 ; 25: 559-566.
81. Gee BC Seborrhoeic dermatitis. Clin Evid. 2004 ; 2344-2352.
82. Gupta AK, Bluhm R., Cooper EA, Summerbell RC, Batra R. Seborrheic dermatitis. Dermatol Clin. 2003 ; 21: 401-412.
83. Gupta AK, Madzia SE, Batra R. Etiology and management of seborrheic dermatitis. Dermatology. 2004 ; 208: 89-93.
84. Schwartz RA, Janusz CA, Janniger CK Seborrheic dermatitis: an overview. Am Fam Physician. 2006 ; 74: 125-130.
85. Hurwitz S. An overview of dermatologic diagnosis. In: Clin Pediatr Dermatol. Philadelphia, PA: WB Saunders ; 1981: 1-5.
86. Janniger CK Infantile seborrheic dermatitis: an approach to cradle cap. Cutis. 1993 ; 51: 233-235.
87. Mimouni K., Mukamel M., Zeharia A., Mimouni M. Prognosis of infantile seborrheic dermatitis. J Pediatr. 1995 ; 127: 744-746.
88. Foley P., Zuo Y., Plunkett A., Merlin K., Marks R. The frequency of common skin conditions in preschool-aged children in Australia: seborrheic dermatitis and pityriasis capitis (cradle cap). Arch Dermatol. 2003 ; 139: 318-322.
89. Elewski BE Clinical diagnosis of common scalp disorders. J Investig Dermatol Symp Proc. 2005 ; 10: 190-193.
90. Williams JV, Eichenfield LF, Burke BL, Barnes-Eley M., Friedlander SF Prevalence of scalp scaling in pre-pubertal children. Pediatrics. 2005 ; 115: e1 - e6.
91. Johnson BA, Nunley JR Treatment of seborrheic dermatitis. Am Fam Physician. 2000 ; 61: 2703-2710.
92. Gupta AK, Nicol K., Batra R. Role of antifungal agents in the treatment of seborrheic dermatitis. Am J Clin Dermatol. 2004 ; 5: 417-422.
93. Braza TJ, DiCarlo JB, Soon SL, Mccall CO Tacrolimus 0.1% ointment for seborrhoeic dermatitis: an open-label pilot study. Br J Dermatol. 2003 ; 148: 1242-1244.
94. Xolegel Gel [package insert]. Princeton, NJ: Barrier Therapeutics Inc ; 2006.
95. Meshkinpour A., Sun J., Weinstein G. An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis. J Am Acad Dermatol. 2003 ; 49: 145-147.
96. Crutchfield CE III. Pimecrolimus: a new treatment for seborrheic dermatitis. Cutis. 2002 ; 70: 207-208.
97. Brownell I., Quan LT, Hsu S. Topical pimecrolimus in the treatment of seborrheic dermatitis. Dermatol Online J. 2003 ; 9: 13.
98. Rallis E., Nasiopoulou A., Kouskoukis C., Koumantaki E. Pimecrolimus cream 1% can be an effective treatment for seborrheic dermatitis of the face and trunk. Drugs Exp Clin Res. 2004 ; 30: 191-195.
99. Warshaw E., Wohlhuter J., Drake D., et al. Randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis [abstract 920]. J Invest Dermatol. 2005 ; 125: A3.
100. Cunha PR Pimecrolimus cream 1% is effective in seborrhoeic dermatitis refractory to treatment with topical corticosteroids. Acta Derm Venereol. 2006 ; 86: 69-70.
101. Akhavan A., Cohen SR The relationship between atopic dermatitis and contact dermatitis. Clin Dermatol. 2003 ; 21: 158-162.
102. Krol A., Krafchik B. The differential diagnosis of atopic dermatitis in childhood. Dermatol Ther. 2006 ; 19: 73-82.
103. Scheinfeld N. Diaper dermatitis: a review and brief survey of eruptions of the diaper area. Am J Clin Dermatol. 2005 ; 6: 273-281.
104. Ward DB, Fleischer AB Jr, Feldman SR, Krowchuk DP Characterization of diaper dermatitis in the United States. Arch Pediatr Adolesc Med. 2000 ; 154: 943-946.
105. Vusion [package insert]. Princeton, NJ: Barrier Therapeutics, Inc ; 2006.
106. Mercader P., Cuadra-Oyanguren J., Rodríguez-Serna M., Pitarch-Bort G., Fortea-Baixauli JM Treatment of protein contact dermatitis with topical tacrolimus. Acta Derm Venereol. 2005 ; 85: 555-556.
107. Nakada T., Iijima M., Maibach HI Eyeglass frame allergic contact dermatitis: does tacrolimus prevent recurrences ? Contact Derm. 2005 ; 53: 219-221.
108. Anderson BE, Marks JG Jr, Mauger DT Efficacy of tacrolimus ointment in the prevention and treatment of contact dermatitis. Dermatitis. 2004 ; 15: 158-159.
109. Alomar A., Puig L., Gallardo CM, Valenzuela N. Topical tacrolimus 0.1% ointment (Protopic®) reverses nickel contact dermatitis elicited by allergen challenge to a similar degree to mometasone furoate 0. 1% with greater suppression of late erythema. Contact Derm. 2003 ; 49: 185-188.
110. Queille-Roussel C., Graeber M., Thurston M., et al. SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Derm. 2000 ; 42: 349-350.
111. Belsito DV, Fowler JF Jr, Marks JG Jr, et al. Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis. Cutis. 2004 ; 73: 31-38.
112. Zhai H., Villarama CD, Hasan Hafeez Z., Maibach HI Efficacy of a topical agent, MAS063D ('Atopiclair'), in the treatment of sodium lauryl sulphate-induced irritant contact dermatitis. Exog Dermatol. 2003 ; 2: 301-305.